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The speciﬁc associations between antidepressant treatment and alterations in the levels of cytokines remain to be elucidated. In
this study, we aimed to explore the role of IL-2, IL-4, IL-12, TNF-α,T G F - β1, and MCP-1 in major depression and to investigate the
eﬀects of sertraline therapy. Cytokine and chemokine levels were measured at the time of admission and 8 weeks after sertraline
treatment. Our results suggest that the proinﬂammatory cytokines (IL-2, IL-12, and TNF-α) and MCP-1 were signiﬁcantly higher,
whereas anti-inﬂammatory cytokines IL-4 and TGF-β1 were signiﬁcantly lower in patients with major depression than those of
healthy controls. It seems likely that the sertraline therapy might have exerted immunomodulatory eﬀects through a decrease in
the proinﬂammatory cytokine IL-12 and an increase in the anti-inﬂammatory cytokines IL-4 and TGF-β1. In conclusion, our
results indicate that Th1-, Th2-, and Th3-type cytokines are altered in the depressed patients and some of them might have been
corrected by sertraline treatment.
Copyright © 2007 Levent Sutcigil et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
There is now evidence that major depression is accompanied
by signiﬁcant changes in cell-mediated and humoral immu-
nity, and these changes may be related to the pathophysi-
ology or pathogenesis of that illness (Connor and Leonard
[1], Dantzer et al. [2], Kim et al. [3], Licinio and Wong [4]),
yet data are inconsistent. Some studies have shown that ma-
jor depression is associated with dysregulation of immune
mediators, such as the rise in interleukin (IL)-1β,I L - 6 ,I L -
12, soluble IL-6R, IL-2, soluble IL-2R, IL-1Ra, and IFN-γ
(Kaestner et al. [5], Kim et al. [3], Maes et al. [6], Maes et al.
[7], Maes et al. [8], Maes [9], Maes et al. [10], Seidel et al.
[11]). However, conﬂicting results have also been described
(Brambilla and Maggioni [12], Brambilla et al. [13], Carpen-
ter et al. [14], Rothermundt et al. [15]). These changes have
been considered in terms of the imbalance between individ-
ual pro- and anti-inﬂammatory cytokines and the T helper 1
(Th1) and T helper 1 (Th2) imbalance in major depression.
On the other hand, an enhanced secretion of such proin-
ﬂammatory cytokines would not only lead to activation of
T and B lymphocytes, but also could aﬀect the brain and
elicit various symptoms of depression, such as loss of ap-
petite, listlessness, and sleep disturbances (Maes [16]). Fur-
thermore, only few clinical studies report whether the pa-
tients that are included in the sample receive antidepres-
sant treatment or not. Most of these studies are inconsis-
tent and based on data generated from ex vivo or in vitro
immunological evaluations showing that the antidepressant
treatmentusuallynormalizesthechangesinbothcellularand
humoralimmunitythatoccurindepression(NeveuandCas-
tanon [17]). Although the precise mechanism of how the an-
tidepressants act is uncertain, there is some other evidence
in the literature suggesting that they could reduce the re-
lease of pro-inﬂammatory cytokines and other immunologi-
cal factors (Lanquillon et al. [18], Leonard [19]). It has been2 Clinical and Developmental Immunology
reported that antidepressants can decrease the Th1/Th2 or
proinﬂammatory/anti-inﬂammatory cytokine ratio (Kubera
et al. [20], Maes [21]) and it has been hypothesized that cy-
tokine hypersecretion may be involved in the pathophysi-
ology of depressive disorders (Leonard [19]). Nevertheless,
treatment of depressive disorders with antidepressants is not
always accompanied by a reduction in the concentrations of
proinﬂammatorycytokines(Weizmanetal.[22],Maes[16]).
Thus, the speciﬁc associations between antidepressant treat-
ment and alterations in the levels of cytokines remain to be
elucidated.
Classically, IL-2 and IL-12 are Th1 type proinﬂamma-
tory cytokines, but IL-4 and transforming growth factor beta
(TGF-β)areTh2andTh3typeanti-inﬂammatorycytokines,
respectively. These type cytokines are secreted by T lympho-
cytes while tumor necrosis factor-alpha (TNF-α) generally
secreted by monocytes and macrophages which is the other
pro-inﬂammatory cytokine. The goals of this study are (1) to
determine the IL-2, IL-4, IL-12, TNF-α, TGF beta-1 (TGF-
β1), and monocyte chemotactic protein-1 (MCP-1) in our
sample of depressed patients, (2) to evaluate whether these
characteristics diﬀer between patients with major depression
and age- and sex-matched healthy controls, and (3) to in-
vestigate the eﬀect of treatment with, a selective serotonin
reuptake inhibitor (SSRI) antidepressant, sertraline on these
parameters.
2. MATERIALS AND METHODS
Our study included 30 only ﬁrst episode unipolar depressive
outpatients consecutively admitted to our psychiatry depart-
ment. Two patients dropped out of the study because acute
medical disease. Five patients who fail to respond to ser-
traline therapy were also excluded at the end of the study.
Twenty three (11 females, 12 males) patients have completed
the study. Twenty ﬁve healthy volunteers (12 females, 13
males) were included the study as controls. Informed con-
sent was obtained from all subjects. The study protocol was
approved by the ethic committee of G¨ ulhane Military Medi-
cal Academy.
All depressed patients fulﬁlled the DSM-IV criteria for
major depressive episode. The patients have been seen by a
psychiatrist in the outpatient unit of our department. Those
who were meeting the criteria of the research have been re-
ferred to the primary investigator (PI) who is also a psy-
chiatrist. The healthy controls have been recruited from the
employees of the medical academy. Initially, these subjects
are selected after detailed physical and mental examinations.
Controls which met the inclusion criteria were interviewed
by the PI similar as the patients. Controls were matched to
the subjects according to their age and gender.
The severity of the depression was quantiﬁed by the
HamiltonDepressionRatingScale(HDRS)onpre-andpost-
treatmentwithsertraline(50–100mg/day,8weeks).Thepre-
and post-HDRS assessments were conducted only by the PI.
Clinical and laboratory data were anonymous. All ratings
were evaluated by the PI blinded to the immunological pro-
ﬁles. All parameters were repeated after the treatment with
sertraline.Aftertreatment,thepatientswhichwerenolonger
meeting diagnostic criteria of unipolar major depressive dis-
order have been accepted as responders. The response rate
was 77%.
Exclusion criteria were any additional axis I or axis II
DSM-IV diagnosis, current pregnancy, acute or chronic in-
fections within the past month, autoimmune, allergic, neo-
plastic, or endocrine diseases and other acute physical dis-
orders, including surgery or infarction of the heart or brain
within the past 3 months. Patients exposed to any drug
including antidepressants, nonsteroidal anti-inﬂammatory
drugs, and oral contraceptives in the past 6 weeks were also
excluded. Healthy volunteers were also interviewed and in
addition to the above exclusion criteria, those with no life-
time or current diagnosis of any psychiatric disorders were
included as the control group.
After an overnight fast, blood samples for the assays were
collected at 9 a.m. (±30 minutes) from patients with ma-
jor depression and healthy volunteers. Ten millilitres venous
bloodwasdrawnandcentrifugedat3000rpmfor10minutes
for the measurements of IL-2, IL-4, IL-12, TGF-β1, TNF-
α, and MCP-1 levels. All sera samples were stored at –70◦C
until run. All immunological parameters were determined
by Enzyme Immunoassay method with Bender MedSystems
kits (Bender MedSystems GmbH Campus Vienna Biocenter
2 A-1030, Vienna, Austria). According to kit prescription,
the intra- and interassay coeﬃcients of variation (CVs) were
4.7% and8.7%forMCP-1,6.7%and8.5%forTGF-β1,3.0%
and 4.8% for IL-12, 5.2% and 8.0% for IL-2, 4.8% and 5.6%
for IL-4, and 6.9% and 7.4% for TNF-α,r e s p e c t i v e l y .
The same procedures have been applied during post-
treatment assessment. The duration of treatment was min-
imum 8 weeks and posttreatment assessment has been per-
formed in the ﬁrst week after end of the 8th week.
3. STATISTICAL ANALYSIS
Data were analyzed with SPSS (SPSS Inc., Ill, USA) statis-
tical software. Descriptives were quoted as the mean ± SD.
Changes in HDRS and immune measurements were calcu-
lated. The relations among these changes were assessed with
Spearman’s rho coeﬃcient of correlation. Before and after
values of the parameters were compared with “paired sam-
ples t test.” We used “independent samples t t e s t ”t oc o m p a r e
the parameter values of the control and treatment groups.
For multiple tests, we used Bonferroni correction. Pearson
coeﬃcient of correlation for the parameters was calculated.
A P value less than or equal to .05 was evaluated as statisti-
cally signiﬁcant.
4. RESULTS
The clinical and immunological characteristics of the pa-
tients with major depression and healthy controls and the
results of comparisons are shown in Table 1. There was no
diﬀerence between both patient groups and controls with re-
spect to age (P = .835) and sex (P = .945). The mean lev-
els of HDRS (P < .001), IL-2 (P < .001), IL-12 (P < .001),
TNF-α (P < .001), and MCP-1 (P < .001) were signiﬁcantly
higher in patients with major depression than in controls.Levent Sutcigil et al. 3
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Figure 1: Hamilton depression rating scale (HDRS) levels before
(BT) and after (AT) sertraline treatment.
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Figure 2: Interleukin-4 (IL-4) levels before (BT) and after (AT) ser-
traline treatment.
As compared with the controls, the mean levels of IL-4 (P <
.001) and TGF-β1( P < .001) were signiﬁcantly lower in pa-
tient group. The nonresponders to sertraline have not been
included to the study, since the number of nonresponders
was only ﬁve which could not be included in statistical anal-
ysis.
In the patient group, clinical and immunological char-
acteristics before and after treatment with sertraline and the
results of comparisons are given in Table 2. The mean levels
of HDRS (P < .001), TNF-α (P < .001), MCP-1 (P < .001),
IL-2 (P < .001), and IL-12 (P < .001) decreased signiﬁcantly
after the sertraline treatment, whereas IL-4 (P = .001) and
TGF-β1( P < .001) increased signiﬁcantly. However, only re-
duction of HDRS (r = 0.966; P < .001, Figure 1) and IL-12
(r = 0.837; P < .001, Figure 3) and increment of IL-4 (r =
0.631; P = .001, Figure 2)a n dT G F - β1( r = 0.524; P = .010,
Figure 4) after therapy were found to be correlated with ser-
traline treatment. The reduction of IL-2, TNF-α,a n dM C P - 1
after treatment did not correlate signiﬁcantly with sertraline
therapy.
Change in HDRS and the other immune measurements
were not signiﬁcantly correlated. There was a positive corre-
lation between both changes in IL-12 and IL-2 (ρ = 0.792;
P<. 001).
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Figure 3: Interleukin-12 (IL-12) levels before (BT) and after (AT)
sertraline treatment.
5. DISCUSSION
In this study, we aimed to explore the role of IL-2, IL-4, IL-
12,TNF-α,andT GF -β1,whichrepresentthecytokinesofthe
Th1, Th2, and Th3 types, and MCP-1 in major depression,
andtoinvestigate theeﬀectsofsertralinetherapy.Ourresults
suggest that the proinﬂammatory cytokines (IL-2, IL-12, and
TNF-α) and MCP-1 were signiﬁcantly higher, whereas anti-
inﬂammatory cytokines IL-4 and TGF-β1 were signiﬁcantly
lowerinpatientswithmajordepressionthanthoseofhealthy
controls.Itseemslikelythatthesertralinetherapymighthave
exertedimmunomodulatoryeﬀectsthroughadecreaseinthe
proinﬂammatory cytokine IL-12 and an increase in the anti-
inﬂammatory cytokines IL-4 and TGF-β1.
In agreement with our ﬁndings, previous studies in ma-
jor depressive disorder report that the elevation in IL-2 pro-
duction during depressive state (Seidel et al. [23], Schlatter
et al. [24]). This IL-2 overproduction could be integrated in
the inﬂammatory response system, which is activated during
depression, and is consistent with the shift Th1/Th2 mecha-
nism. In addition, in vitro studies with human whole blood
have reported that sertraline is able to inhibit the production
of IL-2 (Kubera et al. [25], Kubera et al. [20]). Conversely,
other authors reported decreased production IL-2 in major
depression (Pav´ on et al. [26]) and a normalizing trend af-
ter treatment (Kanba et al. [27], Weizman et al. [22]). The
reason for the discrepancy between these studies is unclear,
and due to the numerous methodological dissimilarities be-
tween studies, it is diﬃcult to speculate.
As others (Myint et al. [28]), we demonstrated that de-
pressed patients had lower IL-4 levels compared to normal
controls. Nevertheless, Pav´ on et al. [26] reported higher IL-4
levels in patients with major depression than controls, while
others observed unchanged IL-4 levels (Natelson et al. [29],
Schlatter et al. [24]). On the other hand, in contrast to our
ﬁndings, Myint et al. [28]r e p o r t e dt h a tI L - 4l e v e l sw e r er e -
duced in depressed patients after the 8-week treatment. Dif-
ferences among studies are likely to be attributable to factors
such as patient diagnosis, diagnostic criteria utilized, patient
demographic, and the immune measured assayed.
Another ﬁnding of our study, like others (Kim et al.
[3], Lee and Kim [30]), is that depressive patients had4 Clinical and Developmental Immunology
Table 1: Clinical and immunological features in patient and control groups.
Parameters
Patients with major Healthy controls tP
depression (n = 23) (n = 25)
Age, years 34.78 ±7.42∗ 34.32 ±7.80 0.210 NS
Hamiltondepression
rating scale
28.39 ±4.53 4.20 ± 1.80 23.927 <.001
Interleukin-2 (pg/ml) 33.45 ±6.37 14.65 ±2.79 13.053 <.001
Interleukin-4 (pg/ml) 3.43 ±0.51 7.80 ± 1.75 11.917 <.001
Interleukin-12 (pg/ml) 16.50 ±3.74 6.17 ± 1.86 11.978 <.001
Tumor necrosis factor-α
(pg/ml)
77.68 ±16.21 36.04 ± 12.63 9.972 <.001
Transforminggrowth
factor-β1( n g / m l )
1.52 ±0.21 3.09 ± 0.46 15.361 <0.001
Monocytechemotactic
protein-1 (pg/ml)
84.54 ±12.54 48.09 ±8.19 11.647 <0.001
∗Mean ± SD.
Table 2: Eﬀect of sertraline therapy on clinical and immunological features in patient with major depression.
Parameters Before sertraline therapy After sertraline therapy tP
Hamiltondepression
rating scale
28.39 ±4.53 13.57 ±2.21 28.885 <.001
Interleukin-2 (pg/ml) 33.45 ±6.37 19.29 ±4.05 10.113 <.001
Interleukin-4 (pg/ml) 3.43 ±0.51 6.25 ±1.17 14.414 <.001
Interleukin-12 (pg/ml) 16.50 ±3.74 10.45 ±3.61 13.821 <.001
Tumor necrosis factor-α
(pg/ml)
77.68 ±16.21 53.85 ±8.30 7.199 <.001
Transforminggrowth
factor-β1( n g / m l )
1.52 ±0.21 2.68 ±0.62 10.310 <.001
Monocytechemotactic
protein-1 (pg/ml)
84.54 ±12.54 54.79 ±10.33 10.440 <.001
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Figure 4: Transforming growth factor β1( T G F -β1) levels before
(BT) and after (AT) sertraline treatment.
signiﬁcantly higher plasma levels of IL-12 than did nor-
mal controls, and IL-12 levels were decreased after sertraline
treatment. The ﬁnding of increased IL-12 in patients with
major depression, together with increased IL-2, may be con-
sidered as additional evidence for activation of Th1-type im-
mune response during major depression.
In consistency with previous reports (Kubera et al. [25],
Kubera et al. [20], Mikova et al. [31], Tuglu et al. [32]), our
results suggested that in comparison with healthy controls,
patients with major depression have signiﬁcantly higher lev-
els of TNF-α, which decrease after sertraline treatment. Like-
wise, Lanquillon et al. [18] reported that the production of
TNFα by peripheral blood mononuclear cells is signiﬁcantly
higher in depressed patients than in normal controls. How-
ever, other authors (Brambilla and Maggioni [12], Haack et
al. [33]) reported no alteration found in TNF-α level in pa-
tients with major depression. The variable results, to some
extent, may be associated with the characteristics of the ill-
ness, as well as the gender of the patients.
In the current study, TGF-β1, the Th3 cytokine, showed
lower value in patients with major depression than healthy
controls, and plasma TGF-β1 levels were signiﬁcantly in-
creased after 8-week treatment with sertraline as previously
reported (Lee and Kim [30], Myint et al. [28]). Since TGF-
β1 has multiple suppressive actions on T cells, B cells,
macrophages, and other cells, sertraline may change theLevent Sutcigil et al. 5
proinﬂammatory/anti-inﬂammatory cytokine balance via
increased TGF-β1 levels in major depression.
Similar to our results, high levels of MCP-1 have been
reported previously in untreatedpatients with major depres-
sion (Rajagopalan et al. [34]). Conversely, some data are in-
consistent (Motivala et al. [35]), but limitations of this study
which must be addressed are due to the relatively small size
of the groups.
Some potential limitations of the current study should
be noted. First, the sample size is too small and the design
is too simple. Due to our research capabilities and proto-
col, the samples from the controls could not be obtained at
thepostassessment.Afurtherreplicationstudythatexamines
the eﬀects of each antidepressant on these immunological
parameters in larger numbers of patients will be warranted.
Second,sincewecollectedtheplasmasamplesonlyinthebe-
ginning and at the end of an 8-week treatment period, some
signiﬁcant changes in cytokine and chemokine levels could
have been missed. Third, it is still unclear whether altered
cytokine and chemokine levels are responsible for the provo-
cation of depression or merely represent secondary features
of the illness. We also would like to declare that it is obvi-
ous that relying upon diagnosis by clinicians is less optimal
thanstructuredinterview.Thisisoneofthelimitationsofthe
study. Finally, our results show the eﬀect of sertraline only in
responders group.
In conclusion, our results indicate that Th1, Th2, and
Th3 are altered in the depressed patients. Some of them may
have been corrected by sertraline treatment. These results
support the concept that depressive disorders have been as-
sociated with changes of various aspects of the immune re-
sponse, both immunoactivation and immunosuppression.
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